These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16385174)

  • 1. Symptomatic hypocalcemia due to oral risedronate therapy.
    Dogru T; Sonmez A; Tasci I; Genc H
    Indian J Med Sci; 2005 Dec; 59(12):542-3. PubMed ID: 16385174
    [No Abstract]   [Full Text] [Related]  

  • 2. Review of the safety and efficacy of risedronate for the treatment of male osteoporosis.
    Bobba R; Adachi JD
    Clin Interv Aging; 2007; 2(3):275-82. PubMed ID: 18044178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risedronate induced transient ocular myasthenia.
    Raja V; Sandanshiv P; Neugebauer M
    J Postgrad Med; 2007; 53(4):274-5. PubMed ID: 18097124
    [No Abstract]   [Full Text] [Related]  

  • 4. Profound refractory hypocalcemia after thyroidectomy in a patient receiving chronic oral bisphosphonate therapy.
    Richmond BK
    Am Surg; 2005 Oct; 71(10):872-3. PubMed ID: 16468539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
    Iwamoto J; Takeda T; Sato Y
    Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone.
    Whitson HE; Lobaugh B; Lyles KW
    Bone; 2006 Oct; 39(4):954-8. PubMed ID: 16769264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates. A cornerstone of osteoporosis treatment.
    Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171
    [No Abstract]   [Full Text] [Related]  

  • 8. [Efficacy and tolerability of risedronate for the treatment of osteoporosis].
    Kishimoto H
    Clin Calcium; 2008 Oct; 18(10):1417-26. PubMed ID: 18830038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypocalcemia after alendronate therapy in a patient with celiac disease.
    Meek SE; Nix K
    Endocr Pract; 2007; 13(4):403-7. PubMed ID: 17669718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].
    Kishimoto H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():365-8. PubMed ID: 18161133
    [No Abstract]   [Full Text] [Related]  

  • 11. [Severe oesophagus injury as a complication during treatment with risedronic acid].
    Bijlsma A; Blokzijl H; Vecht J
    Ned Tijdschr Geneeskd; 2008 Sep; 152(39):2105-7. PubMed ID: 18856023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risedronate has no adverse effects on mouse haematopoiesis.
    Sefc L; Broulík P; Pelichovská T; Necas E
    Folia Biol (Praha); 2007; 53(4):143-5. PubMed ID: 17706020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a role for combination therapy for osteoporosis?
    Cosman F
    Endocrine; 2013 Aug; 44(1):5-7. PubMed ID: 23619961
    [No Abstract]   [Full Text] [Related]  

  • 14. Monthly risedronate (Actonel) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2008 Sep; 50(1294):69-70. PubMed ID: 18772843
    [No Abstract]   [Full Text] [Related]  

  • 15. Yearly zoledronic acid in postmenopausal osteoporosis.
    Karam R; Camm J; McClung M
    N Engl J Med; 2007 Aug; 357(7):712-3; author reply 714-5. PubMed ID: 17703529
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of alendronate and risedronate in preventing and treating osteoporosis.
    Peters ML; Leonard M; Licata AA
    Cleve Clin J Med; 2001 Nov; 68(11):945-51. PubMed ID: 11718433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous bilateral subtrochanteric fractures following risedronate therapy.
    Ovaska MT; Mäkinen TJ; Madanat R
    J Orthop Sci; 2011 Jul; 16(4):467-70. PubMed ID: 21779886
    [No Abstract]   [Full Text] [Related]  

  • 18. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.
    Sato Y; Honda Y; Iwamoto J
    Neurology; 2007 Mar; 68(12):911-5. PubMed ID: 17372126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risedronate: a new oral bisphosphonate.
    Roll KT
    Clin Ther; 2002 May; 24(5):835-6. PubMed ID: 12075950
    [No Abstract]   [Full Text] [Related]  

  • 20. Fracture protection in osteoporosis with risedronate.
    Boonen S; Vanderschueren D
    Hosp Med; 2004 Sep; 65(9):535-40. PubMed ID: 15449490
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.